These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306 [TBL] [Abstract][Full Text] [Related]
9. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Dawwas GK; Brown J; Dietrich E; Park H Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988 [TBL] [Abstract][Full Text] [Related]
11. How I treat heavy menstrual bleeding associated with anticoagulants. Boonyawat K; O'Brien SH; Bates SM Blood; 2017 Dec; 130(24):2603-2609. PubMed ID: 29092828 [TBL] [Abstract][Full Text] [Related]
12. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Lethaby AE; Cooke I; Rees M Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK. Folkerts K; Broughton J; Sheikh U; Mckaig S J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687 [No Abstract] [Full Text] [Related]
14. Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report. Giustozzi M; Vedovati MC; Agnelli G Blood Coagul Fibrinolysis; 2018 Jun; 29(4):391-394. PubMed ID: 29346128 [TBL] [Abstract][Full Text] [Related]
15. Abnormal uterine bleeding in users of rivaroxaban and apixaban. Jacobson-Kelly AE; Samuelson Bannow BT Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):538-541. PubMed ID: 33275697 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830 [TBL] [Abstract][Full Text] [Related]
17. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Bryk AH; Piróg M; Plens K; Undas A Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297 [TBL] [Abstract][Full Text] [Related]
19. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly]. Páramo JA Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406 [No Abstract] [Full Text] [Related]
20. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting. Yassine D; Brown EN; Putney D; Fasoranti O J Oncol Pharm Pract; 2020 Oct; 26(7):1650-1656. PubMed ID: 32063102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]